Generation of clinical-grade CD19-specific CAR-modified CD81 memory stem cells for the treatment of human B-cell malignancies

Blood

Volumn 128, Issue 4, 2016, Pages 519-528

  Sabatino, Marianna ^a   Hu, Jinhui ^b   Sommariva, Michele ^a,c   Gautam, Sanjivan ^b   Fellowes, Vicki ^b   Hocker, James D ^b   Dougherty, Sean ^b   Qin, Haiying ^b   Klebanoff, Christopher A ^b   Fry, Terry J ^b   Gress, Ronald E ^b   Kochenderfer, James N ^b   Stroncek, David F ^a   Ji, Yun ^b   Gattinoni, Luca ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; GAMMA INTERFERON; GLUCOSE TRANSPORTER 1; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; L SELECTIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; TRANSCRIPTOME; TUMOR NECROSIS FACTOR; TWS 119; UNCLASSIFIED DRUG; CD19 MOLECULE, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CANCER GRADING; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EFFECTOR CELL; GENE EXPRESSION PROFILING; GENETIC ENGINEERING; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; MEMORY T LYMPHOCYTE; METABOLIC FITNESS; METABOLIC PARAMETERS; MOUSE; NONHUMAN; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; STEM CELL; STEM CELL TRANSPLANTATION; T LYMPHOCYTE ACTIVATION; T MEMORY STEM CELL; TRANSCRIPTOMICS; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ADOPTIVE TRANSFER; ANIMAL; DRUG SCREENING; GENETICS; HEMATOLOGIC NEOPLASMS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; TRANSPLANTATION; TUMOR CELL LINE;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD19; B-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOLOGIC MEMORY; MICE; MICE, INBRED NOD; MICE, SCID; RECEPTORS, ANTIGEN, T-CELL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85011286658     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-11-683847     Document Type: Article

References (67)

1. June CH, Riddell SR, Schumacher TN. Adoptive cellular therapy: A race to the finish line. Sci Transl Med. 2015;7(280):280ps7.
2. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012;12(4):269-281.
3. Gattinoni L, Klebanoff CA, Restifo NP. Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer. 2012;12(10):671-684.
4. Mahnke YD, Brodie TM, Sallusto F, Roederer M, Lugli E. The who's who of T-cell differentiation: human memory T-cell subsets. Eur J Immunol. 2013;43(11):2797-2809.
5. Klebanoff CA, Gattinoni L, Restifo NP. Sorting through subsets: Which T-cell populations mediate highly effective adoptive immunotherapy? J Immunother. 2012;35(9):651-660.
6. Gattinoni L, Klebanoff CA, Palmer DC, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD81 T cells. J Clin Invest. 2005;115(6):1616-1626.
7. Klebanoff CA, Gattinoni L, Torabi-Parizi P, et al. Central memory self/tumor-reactive CD81 T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA. 2005;102(27):9571-9576.
8. Hinrichs CS, Borman ZA, Cassard L, et al. Adoptively transferred effector cells derived from naive rather than central memory CD81 T cells mediate superior antitumor immunity. Proc Natl Acad Sci USA. 2009;106(41):17469-17474.
9. Gattinoni L, Lugli E, Ji Y, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011;17(10):1290-1297.
10. Gattinoni L, Zhong XS, Palmer DC, et al. Wnt signaling arrests effector T cell differentiation and generates CD81 memory stem cells. Nat Med. 2009;15(7):808-813.
11. Sommermeyer D, Hudecek M, Kosasih PL, et al. Chimeric antigen receptor-modified T cells derived from defined CD8(1) and CD4(1) subsets confer superior antitumor reactivity in vivo. Leukemia. 2016;30(2):492-500.
12. Lugli E, Pinti M, Nasi M, et al. Subject classification obtained by cluster analysis and principal component analysis applied to flow cytometric data. Cytometry A. 2007;71(5): 334-344.
13. Thome JJ, Yudanin N, Ohmura Y, et al. Spatial map of human T cell compartmentalization and maintenance over decades of life. Cell. 2014; 159(4):814-828.
14. Appay V, Dunbar PR, Callan M, et al. Memory CD81 T cells vary in differentiation phenotype in different persistent virus infections. Nat Med. 2002;8(4):379-385.
15. Mackall CL, Fleisher TA, Brown MR, et al. Distinctions between CD81 and CD41 T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood. 1997;89(10):3700-3707.
16. Singh N, Perazzelli J, Grupp SA, Barrett DM. Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. Sci Transl Med. 2016;8(320):320ra3.
17. Turtle CJ, Hanafi LA, Berger C, et al. CD19 CART cells of defined CD41:CD81 composition in adult B cell ALL patients [published online ahead of print April 25, 2016]. J Clin Invest. doi:10.1172/JCI85309.
18. Wang X, Popplewell LL, Wagner JR, et al. Phase I studies of central-memory-derived CD19 CAR T cell therapy following autologous HSCT in patients with B-cell NHL. Blood. 2016;127(24):2980-2990.
19. Gattinoni L, Restifo NP. Moving T memory stem cells to the clinic. Blood. 2013;121(4):567-568.
20. Cieri N, Camisa B, Cocchiarella F, et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood. 2013; 121(4):573-584.
21. Xu Y, Zhang M, Ramos CA, et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood. 2014;123(24): 3750-3759.
22. Gomez-Eerland R, Nuijen B, Heemskerk B, et al. Manufacture of gene-modified human T-cells with a memory stem/central memory phenotype. Hum Gene Ther Methods. 2014;25(5):277-287.
23. Lugli E, Gattinoni L, Roberto A, et al. Identification, isolation and in vitro expansion of human and nonhuman primate T stem cell memory cells. Nat Protoc. 2013;8(1):33-42.
24. Kochenderfer JN, Dudley ME, Carpenter RO, et al. Donor-derived CD19-Targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013;122(25):4129-4139.
25. Kochenderfer JN, Feldman SA, Zhao Y, et al. Construction and preclinical evaluation of an anti- CD19 chimeric antigen receptor. J Immunother. 2009;32(7):689-702.
26. Lugli E, Goldman CK, Perera LP, et al. Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates. Blood. 2010; 116(17):3238-3248.
27. Haso W, Lee DW, Shah NN, et al. Anti-CD22- chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. 2013;121(7):1165-1174.
28. Kinjyo I, Qin J, Tan SY, et al. Real-Time tracking of cell cycle progression during CD81 effector and memory T-cell differentiation. Nat Commun. 2015; 6:6301.
29. Buchholz VR, Flossdorf M, Hensel I, et al. Disparate individual fates compose robust CD81 T cell immunity. Science. 2013;340(6132): 630-635.
30. Gerlach C, Rohr JC, Períe L, et al. Heterogeneous differentiation patterns of individual CD81 T cells. Science. 2013;340(6132):635-639.
31. Klebanoff CA, Scott CD, Leonardi AJ, et al. Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy. J Clin Invest. 2016;126(1):318-334.
32. Stemberger C, Dreher S, Tschulik C, et al. Novel serial positive enrichment technology enables clinical multiparameter cell sorting. PLoS One. 2012;7(4):e35798.
33. Hinrichs CS, Spolski R, Paulos CM, et al. IL-2 and IL-21 confer opposing differentiation programs to CD81 T cells for adoptive immunotherapy. Blood. 2008;111(11):5326-5333.
34. Li Y, Bleakley M, Yee C. IL-21 influences the frequency, phenotype, and affinity of the antigenspecific CD8 T cell response. J Immunol. 2005; 175(4):2261-2269.
35. Kochenderfer JN, Dudley ME, Feldman SA, et al. Bcell depletion and remissions of malignancy along with cytokine-Associated toxicity in a clinical trial of anti-CD19 chimeric-Antigen-receptor-Transduced T cells. Blood. 2012;119(12):2709-2720.
36. Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116(20):4099-4102.
37. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 doseescalation trial. Lancet. 2015;385(9967):517-528.
38. Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540-549.
39. Brudno JN, Somerville RP, Shi V, et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol. 2016;34(10):1112-1121.
40. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29(7):917-924.
41. Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009; 114(3):535-546.
42. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol. 1990;10(8):4239-4242.
43. Darrah PA, Patel DT, De Luca PM, et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med. 2007;13(7):843-850.
44. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: A knowledgebased approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545-15550.
45. Willinger T, Freeman T, Hasegawa H, McMichael AJ, Callan MF. Molecular signatures distinguish human central memory from effector memory CD8 T cell subsets. J Immunol. 2005;175(9): 5895-5903.
46. Sukumar M, Liu J, Ji Y, et al. Inhibiting glycolytic metabolism enhances CD81 T cell memory and antitumor function. J Clin Invest. 2013;123(10): 4479-4488.
47. van der Windt GJ, Everts B, Chang CH, et al. Mitochondrial respiratory capacity is a critical regulator of CD81 T cell memory development. Immunity. 2012;36(1):68-78.
48. Ramos CA, Savoldo B, Dotti G. CD19-CAR trials. Cancer J. 2014;20(2):112-118.
49. Sadelain M. CAR therapy: The CD19 paradigm. J Clin Invest. 2015;125(9):3392-3400.
50. Brentjens RJ, Davila ML, Riviere I, et al. CD19-Targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38.
51. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16): 1507-1517.
52. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25.
53. Brentjens RJ, Rivìere I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-Targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118(18):4817-4828.
54. Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7(303):303ra139.
55. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95): 95ra73.
56. Lugli E, Dominguez MH, Gattinoni L, et al. Superior T memory stem cell persistence supports long-lived T cell memory. J Clin Invest. 2013;123(2):594-599.
57. Fuertes Marraco SA, Soneson C, Cagnon L, et al. Long-lasting stem cell-like memory CD81 T cells with a naive-like profile upon yellow fever vaccination. Sci Transl Med. 2015;7(282): 282ra48.
58. Buzon MJ, Sun H, Li C, et al. HIV-1 persistence in CD41 T cells with stem cell-like properties. Nat Med. 2014;20(2):139-142.
59. Precopio ML, Betts MR, Parrino J, et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(1) T cell responses. J Exp Med. 2007; 204(6):1405-1416..
60. Imai N, Ikeda H, Tawara I, Shiku H. Tumor progression inhibits the induction of multifunctionality in adoptively transferred tumorspecific CD81 T cells. Eur J Immunol. 2009; 39(1):241-253.
61. Yuan J, Gnjatic S, Li H, et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci USA. 2008; 105(51):20410-20415.
62. Cavazza A, Moiani A, Mavilio F. Mechanisms of retroviral integration and mutagenesis. Hum Gene Ther. 2013;24(2):119-131.
63. Gattinoni L. The dark side of T memory stem cells. Blood. 2015;125(23):3519-3520.
64. Nagai Y, Kawahara M, Hishizawa M, et al. T memory stem cells are the hierarchical apex of adult T-cell leukemia. Blood. 2015;125(23): 3527-3535.
65. Biasco L, Scala S, Basso Ricci L, et al. In vivo tracking of T cells in humans unveils decade-long survival and activity of genetically modified T memory stem cells. Sci Transl Med. 2015; 7(273):273ra13.
66. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome [published correction appears in Blood. 2015;126(8):1048. Blood. 2014;124(2):188-195.
67. Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014;20(2):119-122.